BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25596550)

  • 1. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
    Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
    Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative proteomics of kinase inhibitor targets and mechanisms.
    Daub H
    ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design, annotation, and application of a kinase-targeted library.
    Xi H; Lunney EA
    Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase profiling assays: a technology review.
    Wang Y; Ma H
    Drug Discov Today Technol; 2015 Nov; 18():1-8. PubMed ID: 26723886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. System-based drug discovery within the human kinome.
    Bamborough P
    Expert Opin Drug Discov; 2012 Nov; 7(11):1053-70. PubMed ID: 22971083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What general conclusions can we draw from kinase profiling data sets?
    Sutherland JJ; Gao C; Cahya S; Vieth M
    Biochim Biophys Acta; 2013 Jul; 1834(7):1425-33. PubMed ID: 23333421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
    Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
    J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
    Hantschel O
    ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinase profiling in early stage drug discovery: sorting things out.
    Defert O; Boland S
    Drug Discov Today Technol; 2015 Nov; 18():52-61. PubMed ID: 26723893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
    Bailey FP; Andreev VI; Eyers PA
    Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in kinase selectivity: insights for target class-focused library screening.
    Posy SL; Hermsmeier MA; Vaccaro W; Ott KH; Todderud G; Lippy JS; Trainor GL; Loughney DA; Johnson SR
    J Med Chem; 2011 Jan; 54(1):54-66. PubMed ID: 21128601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocols for the Design of Kinase-focused Compound Libraries.
    Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
    Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current compound coverage of the kinome.
    Hu Y; Furtmann N; Bajorath J
    J Med Chem; 2015 Jan; 58(1):30-40. PubMed ID: 25051177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 25 years of small molecular weight kinase inhibitors: potentials and limitations.
    Fabbro D
    Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
    Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.